Shifts in trading volume and investor sentiment often provide early signals of emerging opportunities in the stock market. In recent sessions, a group of healthcare-focused equities has shown notable increases in activity, indicating growing market participation. This trend suggests that investors are starting to take a closer look at certain under-the-radar companies.
Cardiol Therapeutics Inc. (CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is building a multi-asset cardiovascular platform by expanding beyond its lead oral therapy into next-generation formulations targeting larger patient populations. This strategic evolution reflects the company’s ambition to address both rare and widespread heart conditions driven by inflammation and fibrosis.
Market Momentum
As of April 10, 2026, CRDL closed at $1.38, unchanged from the previous close, with trading volume (446,875 shares) below its average of 588,345 shares—suggesting a period of consolidation. With a market cap of $154.119M, the stock remains near the upper end of its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.44 continues to reflect significant upside potential as clinical programs advance.
Pipeline Expansion: CRD-38
The company’s next key asset, CRD-38, is a subcutaneous formulation being developed for heart failure, particularly HFpEF. This condition affects a substantial portion of heart failure patients and currently lacks therapies that directly target inflammation. CRD-38 is designed to address both inflammatory and fibrotic pathways, which are central to disease progression.
Preclinical Validation
Preclinical studies have shown that the active compound in CRD-38 may reduce fibrosis, prevent cardiac hypertrophy, and protect against functional decline. These findings support its potential as a disease-modifying therapy in a large and underserved market.
Outlook
As CRD-38 advances toward clinical development, it represents a major opportunity for pipeline diversification. Success in heart failure could significantly expand Cardiol’s addressable market and long-term value proposition.
Gelteq Ltd (GELS)
As of April 10, 2026, Gelteq Ltd (NASDAQ: GELS) started slowly as it slid -9.42% to $0.7. During the day, the stock rose to $0.74 and sank to $0.70. Taking a long-term approach, GELS posted a 52-week range of $0.64-$4.11.
This publicly-traded company’s shares outstanding now amount to $9.44 million, simultaneously with a float of $5.62 million. The organization now has a market capitalization of $7.45 million. Its Quick Ratio in the last reported quarter now stands at 0.27. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for the trailing twelve months, which is currently 67.73. In the same vein, GELS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded as -0.37.
InMed Pharmaceuticals Inc (INM)
InMed Pharmaceuticals Inc (NASDAQ: INM) established an initial surge of 11.14% at $0.72, as the Stock market unbolted on April 10, 2026. During the day, the stock rose to $0.72 and sank to $0.63. Taking a more long-term approach, INM posted a 52-week range of $0.57-$7.98.
In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was 60.38%. Meanwhile, its Annual Earnings per share during the time was 60.38%. This publicly-traded company’s shares outstanding now amount to $2.92 million, simultaneously with a float of $2.91 million. The organization now has a market capitalization of $2.37 million.
